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THE GENETIC BASIS OF DUPUYTREN’S DISEASE. 
Gloria R. Sue, Deepak Narayan. Section of Plastic and Reconstructive Surgery, 
Department of Surgery, Yale University School of Medicine, New Haven, CT. 
 
Dupuytren’s disease is a common heritable connective tissue disorder of poorly 
understood etiology. It is thought that oxidative stress pathways may play a critical role 
in the development of Dupuytren’s disease, given the various disease associations that 
have been observed. We sought to sequence the mitochondrial and nuclear genomes of 
patients affected with Dupuytren’s disease using next-generation sequencing technology 
to potentially identify genes of potential pathogenetic interest. Additionally, we sought to 
compare the genomes between diseased tissue and blood to look for potential somatic 
mutations in the diseased tissue. Upon sequencing and subsequent bioinformatics 
analysis, no differences were observed in the mitochondrial and nuclear genomes 
between diseased tissue and blood. However, when we compared the nuclear genome of 
our patient cohort to a control cohort, we observed some significant genetic differences. 
We identified a number of single nucleotide polymorphisms (SNPs) and mutations that 
are potentially associated with Dupuytren’s disease. Additionally, 2 novel mutations 
leading to amino acid changes were present in all patients in the disease cohort but not in 
the controls. These were mutations in MUC4, encoding mucin 4, and PPP1R32, encoding 
protein phosphatase 1 regulatory subunit 32. These genes warrant further investigation in 
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Dupuytren’s disease is a common heritable connective tissue disorder 
characterized by fibrosis of the palm, causing flexion deformities of the digits that 
ultimately impair hand function. The disease progression is characterized classically by 
the initial appearance of palmar nodules characterized by high cellularity and cell 
proliferation followed by formation of cords in the palm and digits (Figure 1). 
Dupuytren’s disease has a propensity for affecting Caucasian populations, especially 
those of northwestern European origin, as well as the male gender, heavy smokers, and 
those having manual labor as an occupation.1 The average age of onset of disease is 60 
years, with an increasing incidence with increasing age.2 A strong genetic predisposition 
for this disease has also been well established, as demonstrated by concordance rates in 
twin studies and a predilection for familial clustering.3 Even though this disease has been 
known since at least the 1830s, when Baron Guillaume Dupuytren described the clinical 
features of the disease in a famous lecture,4 the etiology of this disease remains poorly 
understood. 
Dupuytren’s disease affects the fascia, or aponeurosis, of the palm. Histologically, 
the diseased tissue contain abundant contractile myofibroblasts,5 which are connected 
intimately with the surrounding extracellular matrix.6 Myofibroblasts are cells involved 
in the granulation stage of wound healing that cause wound contraction7 and the 
alignment of the myofibroblasts along major lines of stress is thought to be the physical 




Figure 1. The clinical presentation of Dupuytren’s disease. Early stage disease (a) with 
prominent cord and small nodules, followed by more advanced stage (b) with dimpling at 
the base of the digit, and subsequently advanced stage disease (c) with severe deformity. 
(From Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren 
disease. Nature reviews. Rheumatology. Dec 2010;6(12):715-726) 
 
Many treatment options exist for the treatment of symptomatic Dupuytren’s 
disease, which typically involves at least a 40° digital flexion contracture. Surgery is 
currently the mainstay of treatment for Dupuytren’s disease and, in increasing 
invasiveness, include fasciotomy, fasciectomy, and dermofasciectomy. Fasciotomy is 
performed percutaneously and is a surgical division of the cord causing the contracture. 
Fasciectomy involves resection of the diseased cord. Dermofasciectomy is the most 
invasive of these procedures and involves a fasciectomy with additional resection of the 
overlying skin, requiring skin grafting to cover the resulting defect. Nonsurgical 
interventions include collagenase injections,8 radiotherapy,9 and steroids.10 Regardless of 
treatment modality, the main complication of treatment for Dupuytren’s disease is the 
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high rate of disease recurrence, which is the reappearance of disease in the affected 
region following treatment. Given the unknown etiology of this disease, the treatment 
remains palliative and is directed by the severity of symptoms. A more complete 
understanding of the etiology of Dupuytren’s disease could potentially lead to the 
development of targeted therapies. 
The leading hypotheses on the etiologic mechanism of Dupuytren’s disease 
include altered immune response causing abnormal wound repair and abnormalities in the 
oxidative stress pathway.11 Autoantibodies against collagen molecules are detected at 
higher levels from patients with Dupuytren’s disease compared to those without the 
disease.12,13 Certain HLA haplotypes also appear to be associated with the disease.14,15 
Additionally, an increased number of macrophages16 and Langerhans cells17 in 
Dupuytren’s-affected tissue compared to controls have been observed. Together, these 
observations suggest a role for immune dysregulation in the development of Dupuytren’s 
disease. 
Many observations also suggest a role for oxidative stress pathway dysregulation 
in the development of this disease, with some recent reports suggesting that 
mitochondrial abnormalities are associated with Dupuytren’s disease. In particular, 
susceptibility to disease has been associated with a single nucleotide polymorphism 
(SNP) in the mitochondrial gene encoding Zf9, a transcription factor,18 and with a 
heteroplasmic mutation in the mitochondrial 16S ribosomal RNA region.19 Mitochondria 
play a critical role in regulating reactive oxygen species generation, with defective 
mitochondria capable of generating excess reactive oxygen species due to electron leak.20 
Dupuytren’s disease has also been clinically associated with comorbidities that include 
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epilepsy21 and diabetes,22 both of which interestingly have been associated with 
mutations of mitochondrial DNA.23,24 Social factors including smoking and alcohol use 
have been associated with Dupuytren’s disease as well,25 which have also been associated 
with mitochondrial abnormalities.26,27 Dupuytren’s tissue has an increased propensity for 
oxygen free radical formation compared to control tissue.28 Oxygen free radicals can in 
turn stimulate proliferation of fibroblasts.29 
In addition to mitochondrial studies, a limited number of nuclear genomic studies 
have been performed. However, the interpretation of these preliminary genetic studies 
remains difficult and the lack of a clear inheritance pattern of Dupuytren’s disease argues 
against a monogenic cause but rather suggests a multifactorial etiology. A recent meta-
analysis combining data from both RNA expression profiling and genome-wide 
association studies has highlighted two potential susceptibility genes for development of 
Dupuytren’s disease: MAFB and PRKX.30 To our knowledge, complete genomic 
sequencing has yet to be utilized in the study of this disease.  
Given that oxidative stress pathways appear to play a critical role in the 
development of Dupuytren’s disease, we sought to better characterize the role of the 
mitochondria in the development of disease. Variations in mitochondrial DNA are 
thought to predispose to common diseases.31 Due to the recent advances in genomic 
sequencing, giving rise to the so-called “next-generation sequencing” making high-
throughput sequencing a new reality, we sought to utilize these novel genomic analytical 
tools to elucidate the genetic basis of Dupuytren’s disease. Among patients with 
Dupuytren’s disease, we sought to sequence both mitochondrial DNA as well as nuclear 
DNA, given the interactions between the cell nucleus and mitochondria. Additionally, 
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most proteins involved in mitochondrial metabolism are nuclear-encoded. As such, 
mutations in certain nuclear genes can mimic features seen in the presence of 
mitochondrial DNA defects.  
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STATEMENT OF PURPOSE 
 
The broad objectives of this research are to better characterize the etiology of 
Dupuytren’s disease with the ultimate goal of optimizing treatment for this disease. Our 
specific research goal is to identify genetic mutations that play a critical role in the 





Due to prior studies suggesting the crucial role of oxidative damage in the development 
of Dupuytren’s disease and the well-characterized role of mitochondria in regulating 
biological oxidation, we hypothesize that there may be unique mitochondrial mutations or 





We seek to sequence and analyze the mitochondrial and nuclear genomes of patients 
affected with Dupuytren’s disease to identify genes of pathogenetic interest. In addition, 
we seek to identify potential differences in the genomes between diseased tissue 






 We identified 23 consecutive patients undergoing open fasciectomy for treatment 
of symptomatic Dupuytren’s disease at the Yale-New Haven Hospital from 2012-2013 
(Figure 2). Informed consent was obtained from patients involved in this study, which 
was approved by the Human Investigation Committee at the Yale University School of 
Medicine. We collected the diseased palmar fascia that was resected during the standard 
fasciectomy. All collected fascia were deemed to be disease-affected, as indicated by 
experienced hand surgeons under visual examination with magnifying surgical loupes. 
All fascial specimens were collected in RNAlater RNA Stabilization Reagent (QIAGEN, 
Venlo, Netherlands) and stored immediately in a -80° freezer until DNA extraction. 
Approximately 1 mL of venous blood were collected from all patients at the time of the 
surgical fasciectomy in lavender Vacutainer Blood Collection Tubes (BD, Franklin 




 DNA from all tissue and blood samples were extracted using the DNeasy Blood 






Figure 2. Distribution of samples from patient cohort; all samples underwent DNA 




Mitochondrial Genome Sequencing 
 
 The extracted DNA samples were subjected to agarose gel and NanoDrop 
(Thermo Scientific, Waltham, MA) OD ratio tests to confirm the purity and concentration 
prior to amplification of mtDNA by proprietary methods (Otogenetics Corporation, 
Norcross, GA). The purified mtDNA was subjected to fragmentation using Covaris 
(Covaris, Inc., Woburn, MA) and profiled using 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). Illumina libraries were made from qualified fragmented 
mtDNA using NEBNext reagents (New England Biolabs, Ipswich, MA) and the resulting 
libraries were tested for size distribution and concentration by the 2100 Bioanalyzer. The 
samples were then sequenced on an Illumina HiSeq2000 which generated paired-end 
reads of 100 nucleotides. Data was analyzed for data quality, coverage, SNP, insertions, 
and deletions using the platform provided by DNAnexus (DNAnexus, Inc., Mountain 
View, CA) using default settings and the mutation percentage set at 1% to include low-
frequency variants. 
 
Nuclear Whole-Exome Sequencing 
 
High-Throughput Barcoded Sample Preparation: 
For each sample, 1 µg of genomic DNA was sheared to a mean fragment 
length of 140 base pairs using focused acoustic energy (Covaris E210, part 
#5000003). Fragmented DNA samples were then transferred to a 96-well plate 
and library construction was completed using a liquid handling robot (Caliper 
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Sciclone, part #SG3-11020-0100). Magnetic AMPure XP beads (Beckman 
Coulter, part #63882) were used to purify the sheared DNA samples and remained 
with the sample throughout library construction. Following each process step, 
DNA was selectively precipitated by weight and re-bound to the beads through 
the addition of a 20% polyethylene glycol, 2.5 M NaCl solution. Following 
fragmentation, T4 DNA polymerase and T4 polynucleotide kinase blunt ended 
and phosphorylated the fragments. The large Klenow fragment then added a 
single adenine residue to the 3' end of each fragment and custom adapters (IDT) 
were ligated using T4 DNA ligase. Adapter-ligated DNA fragments were then 
PCR amplified using custom-made primers (IDT).  During PCR, a unique 6 base 
index was inserted at one end of each DNA fragment. Sample concentration and 
insert size distribution were determined using the Caliper LabChip GX system 
(Caliper, part #122000/B). Samples yielding at least 1 µg of amplified DNA were 
used for capture. 
 
Automated Sample Exome Capture: 
500 ng of prepared genomic DNA library was lyophilized with Cot-1 
DNA and custom adapter blocking oligos (IDT). The dried sample was 
reconstituted according the manufacturer's protocol (Roche/Nimblegen), heat-
denatured, and mixed with biotinylated DNA probes produced by Nimblegen 
(Nimblegen, SeqCap EZ Exome version 2, part #05860504001). Hybridizations 
were performed at 47°C for 68 hours. Once the capture was complete, the samples 
were mixed with streptavidin-coated beads and washed with a series of stringent 
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buffers to remove non-specifically bound DNA fragments. The captured 
fragments were PCR amplified and purified with AMPure XP beads. Capture 
efficiency was evaluated by quantitative PCR (Roche Light Cycler 480, part 
#5015243001). Equal amounts of pre- and post-capture libraries were evaluated at 
4 sites to confirm successful exome enrichment and at 2 other sites to show non-
exome de-enrichment in the captured sample relative to the pre-capture library. 
Samples that met appropriate cut-offs for both were quantified by qRT-PCR using 
a commercially available kit (KAPA Biosystems, part #KK4601) and insert size 
distribution determined with the LabChip GX. Samples showing a yield of at least 
0.5 ng/µl were used for sequencing.   
 
Flow Cell Preparation and Sequencing: 
Sample concentrations were normalized to 2 nM, combined accordingly 
for the number of samples to be sequenced per lane, and loaded onto Illumina 
version 3 flow cells at a concentration that yielded 170-200 million passing filter 
clusters. The samples were sequenced using 75 base pair paired end sequencing 
on an Illumina HiSeq 2000 according to Illumina protocols. The 6 base pair index 
was read during an independent sequencing read that automatically followed the 
completion of read 1 and used an additional sequencing primer (Illumina, part 
#15019606). Data generated during sequencing runs were simultaneously 
transferred to a high performance computing cluster. 
 
In-Run Sequencing Quality Control: 
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A positive control (a prepared bacteriophage Phi X library) provided by 
Illumina was spiked into every lane at a concentration of 0.3% to monitor 
sequencing quality in real time via information displayed by the instrument's 
Sequence Analysis Viewer. Signal intensities, Q30 values (an estimate of the 
number of errors per thousand bases), and Phi X error rates were monitored 
periodically to assess the quality of the ongoing run. 
 
Data Analysis and Storage: 
Signal intensities were converted to individual base calls on the machine 
during each run using the system's Real Time Analysis (RTA) software. Base 
calls were transferred from the machine's dedicated personal computer to the Yale 
High Performance Computing cluster via a 1 Gigabit network mount for 
downstream analysis. Primary analysis - sample de-multiplexing and alignment to 
the human genome - was performed using Illumina's CASAVA 1.8 software suite. 




 Analysis of the sequencing data was performed using open-source software. Data 
were pre-processed using Btrim to remove low quality regions and trim off adaptors.32 
Mapping was then performed using the Burrows-Wheeler Alignment tool33 and 
alignment performed using SAMtools.34 Subsequent annotations were performed using 
personally developed software. For both the mitochondrial genome and whole-exome 
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analyses, each patient’s diseased tissue and blood samples were directly aligned and 
compared to each other to evaluate for any genetic differences. For the whole-exome 
analyses, an additional comparison was made between the diseased tissues from the 
Dupuytren’s disease cohort and the control tissues. The mitochondrial consensus 
sequences were also aligned to the reference mitochondrial genome, the revised 
Cambridge Reference Sequence (National Center for Biotechnology Information 
reference sequence NC_012920). The nuclear genomes were aligned to the reference 
human genome hg19 from the University of California Santa Cruz (National Center for 






Paired Comparisons Between Mitochondrial Diseased Tissue and Blood 
 
 Upon comparing the consensus sequences of the paired tissue and blood samples, 
we did not observe any differences in the mitochondrial genomes for all patient pairs. 
Additionally, no significant differences in degree of heteroplasmy were observed 
between the paired samples. 
 
Identification of Unique Mitochondrial Genome Mutations 
 
 When we compared the mitochondrial consensus sequences of diseased tissue 
from each individual patient to the reference genome, we identified several differences 
common to patients in our cohort (Table 1). Most of these mutations are common 
polymorphisms, including A263G, A750G, A1438G, A4769G, A8860G, and A15326G. 
Excluding common polymorphisms, the only notable difference in the genomes between 
our patient cohort and the reference sequence is the insertion of either a C or CC at 






Table 1. Common mitochondrial genomic changes observed patient cohort. 
 
Comparisons to Prior Mitochondrial Genome Studies 
 
We did not observe among our cohort mitochondrial mutations in either the 
transcription factor Zf9 or the 16S ribosomal RNA region, both of which have been 
previously reported to be associated with the Dupuytren’s disease. 
 
Paired Comparisons of Nuclear Exomes Between Diseased Tissue and Blood 
 
 No nuclear genomic mutations were consistently present in the diseased tissue 
group and were not present in the corresponding blood samples. No distinct patterns of 
mutations were identifiable when comparing nuclear DNA of tissue to blood. 
Mutation  Mitochondrial region 
A263G Control region 
Insertion C/CC at 309 Control region 
A750G 12S RNA 
A1438G 12S RNA 
A4769G NADH dehydrogenase 2 
A8860G ATP synthase F0 subunit 6 
A15326G Cytochrome b 
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Identification of Unique Nuclear Genome Mutations 
 
 Upon comparison of the nuclear genome of the 23 diseased fascial tissues to the 2 
controls, we identified a set of 13 heterozygous SNPs causing amino acid changes present 
in all samples of the disease cohort and not present in the control group (Table 2). We 
also identified 4 SNPs leading to synonymous substitutions that also were present in all 
disease samples but not in control samples: PRB1 gene amino acid Q168, CCDC66 
amino acid T115, MCPH1 amino acid V76, and CA2 amino acid L188. 
 
Comparisons to Prior Nuclear Genome Studies 
 
 We observed 15 unique heterozygous mutations in the MAFB gene among our 
cohort (Table 3), though no single mutation was observed in two or more patients in the 
cohort. These 15 mutations were observed in 10 different patients, with one patient 
accounting for 4 mutations, two patients with 2 mutations, and seven patients with 1 
mutation each. 
 Additionally, we observed 9 unique heterozygous mutations in the PRKX gene 
among our cohort (Table 4), and again no single mutation was observed in two or more 
patients in the cohort. These 9 mutations were observed in 8 different patients, with one 








OR2T12 Olfactory receptor, family 2, subfamily T, 
member 12 
1 T310A 0.413 T104S 
OR2M7 Olfactory receptor, family 2, subfamily 
M, member 7 
1 C571T 0.404 D191N 
OR2T1 Olfactory receptor, family 2, subfamily T, 
member 1 
1 A74G 0.334 H25R 
SSX2IP Synovial sarcoma, X breakpoint 2 
interacting protein 
1 A2058G 0.444 C578R 
MUC4 Mucin 4 3 T11164G n/a T3670P 
MCPH1 Microcephalin 1 8 G1016C 0.316 D314H 
CA3 Carbonic anhydrase 3 8 G174A 0.489 V31I 
SH2D3C SH2 domain containing 3C 9 G209A 0.447 L23F 
HEPN1 Hepatocellular carcinoma, down-
regulated 1 
11 T610C 0.210 W37R 
HEPACAM Hepatic and glial cell adhesion molecule 11 T1058C 0.216 M218V 
PPP1R32 Protein phosphatase 1, regulatory subunit 
32 
11 C234A n/a T34S 
PRB1 Proline-rich protein BstNI subfamily 12 G405T 0.490 P123Q 
PRB1 Proline-rich protein BstNI subfamily 12 C483T 0.374 R149Q 
1Chr = chromosome; 2base sub = base substitution; 3MAF = minor allele frequency 
(source: 1000 Genomes); 4AA sub = amino acid substitution 
Table 2. Thirteen nuclear SNPs leading to amino acid changes observed in all diseased 
tissue that are not present in control tissue.  
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 Our study of the mitochondrial and nuclear genome in patients with Dupuytren’s 
disease clarifies the role of genetics in the development of this disease. Firstly, we did not 
observe differences in the mitochondrial or nuclear genomes of the diseased tissue when 
compared to the blood. This is a significant finding that has previously not been reported. 
This finding suggests that the disease does not develop due to a local accumulation of 
novel mutations in the hand that are not observed in the germline, for which we used 
circulating venous blood as a proxy. Secondly, our genetic analysis did not corroborate 
the reported mitochondrial genetic mutations from prior studies, suggesting that the 
previously reported mutations may be false positive findings or perhaps that the disease 
pathophysiology is heterogeneous and multifactorial.  
 Our interest in the mitochondrial genome was borne out of the reported 
associations between oxidative stress pathway dysregulation and the development of 
Dupuytren’s disease. We read with particular interest two studies by Bayat et al 
suggesting that the disease is associated with a SNP in mitochondrial gene Zf918 and a 
heteroplasmic mutation in the mitochondrial 16S rRNA.19 In the former study, the 
authors used a polymerase chain reaction-restriction fragment polymorphism method to 
genotype the novel SNP in the 3’ untranslated region of the Zf9 gene. A case-control 
study comparing 138 patients with Dupuytren’s disease to 255 control patients without 
disease demonstrated a difference in the genotype and allele frequencies between these 
two groups. Presence of the G allele compared to the A allele was associated with an 
increased risk of developing Dupuytren’s disease (odds ratio 1.9, 95% confidence 
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interval 1.2 to 2.9). This was the first study reporting a positive association with a 
presence of a SNP in Dupuytren’s disease. In the latter study, the authors utilized a 
multiplex denaturing high-performance liquid chromatography approach to sequence 100 
to 600 base pair fragments of the mitochondrial genome. 20 patients with apparent 
maternally inherited Dupuytren’s disease were compared to 20 matched control patients, 
yielding the discovery of a novel heteroplasmic mutation in the mitochondrial 16S rRNA 
present in 90% of the disease cohort and absent from all control patients (P < 0.001). This 
was the first study reporting an association between a mitochondrial heteroplasmic 
mutation and presence of Dupuytren’s disease. However, the findings presented in both 
studies have yet to be corroborated. Subsequent studies by Hu et al and Ojwang et al, 
with Dupuytren’s disease patient cohort sizes of 26 and 40, respectively, failed to 
demonstrate the presence of either results. Additionally, among our patient cohort, we 
also did not find significant differences in the Zf9 gene SNP or identify presence of the 
16S rRNA gene heteroplasmy. Our study benefits from the use of next-generation 
sequencing compared to the Sanger sequencing methods used in the other studies, which 
should theoretically provide a higher level of reliable detection of mitochondrial 
mutations.35 
 One unique mitochondrial mutation that we observed in all patients in our cohort 
is the insertion of cytosine bases at position 309 in the mitochondrial genome. The 
significance of this finding remains unclear. This may be a sequencing artifact, given that 
this cytosine base insertion is located in the midst of a chain of cytosine nucleotides from 
positions 303-308. However, the insertions could presumably also be a true finding and 
potentially represent either a cause of mitochondrial instability or reflect a result of 
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mitochondrial instability. Additional follow-up studies on mitochondrial function in 
patients with Dupuytren’s disease could potentially shed more light on the significance of 
this mutation. One potential study that we intend to pursue is a metabolomics analysis of 
diseased Dupuytren’s tissue, which would be able to quantify abnormalities in the 
mitochondrial metabolites present in diseased tissue. 
 In our study, we did not identify any significant difference in the mitochondrial 
genome of diseased tissue compared to blood samples taken from the same patient. This 
is a critical negative finding. In light of this finding, it is unlikely that de novo mutations 
in the mitochondrial genome are the causative factor in the development of Dupuytren’s 
disease. Similar to nuclear DNA, mitochondrial DNA constantly undergo mutation, with 
studies suggesting that random processes alone are sufficient to give rise to mitochondrial 
DNA mutations.36,37 Studies have even suggested that the accumulation of mutations in 
the mitochondrial genome can result in a significant biochemical defect in their progeny 
cells.37 It is therefore thought that the high mutation rate in mitochondria is due to an 
environment in which there is a relatively high production rate of free radicals by the 
mitochondrial respiratory chain. Our finding that the mitochondrial sequences of diseased 
tissue and the blood within all paired samples showed no differences is significant, and 
suggests that the mitochondria and their associated processes within the diseased tissue is 
appropriately functional. 
Limited nuclear genomic studies have been performed to date to analyze the 
genetic contribution in the development of Dupuytren’s disease. To date, no whole-
exome sequencing studies of Dupuytren’s disease have been reported in the literature. 
However, a variety of related studies have been performed, which include global RNA 
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expression profiling and genome-wide association studies. A recent meta-analysis of 
seven unique sets of global messenger RNA expression microarray studies identified 16 
genes that demonstrate consistently statistically significant dysregulation in patients with 
Dupuytren’s disease (Table 5).30 Additionally, case-control whole genome association 
studies have highlighted 2 genes located within significantly associated loci that have 
also been observed to be differentially expressed in prior microarray studies: MAFB,38 a 
transcription factor that regulates the differentiation of hematopoietic stem cells, and 
PRKX,39 a stimulator of endothelial cell proliferation and migration. However, we did 
not find significant mutations in either of these genes. Only a subset of patients had 
mutations in either gene, and none of the mutations observed were in more than a single 
patient. Therefore, it is unlikely that mutations in these particular genes are associated 
with development of Dupuytren’s disease. However, it remains possible that nearby 
regulators of these two genes may play a role in pathogenesis, which is consistent with 























Table 5. 16 genes have been consistently reported to be dysregulated by mRNA 
expression microarray studies in patients with Dupuytren’s disease. 
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We identified a set of 13 SNPs that give rise to amino acid changes that were 
observed in all diseased tissue but not observed in the control tissue. Most of these SNPs 
are natural variants with relatively high minor allele frequency (MAF) as per the 1000 
Genomes Project. Three of the SNPs are located in three different olfactory receptor 
genes in the G-protein coupled receptor 1 family. The SNP causing the T104S amino acid 
change in OR2T12 has a MAF of 0.413, D191N in OR2M7 has a MAF of 0.404, and 
H25R in OR2T1 has a MAF of 0.334. The SNP in the SSX2IP gene, which encodes for a 
widely expressed protein involved in the mediating cell-cell adherens junctions, is also a 
natural variant with a MAF of 0.444. The MCPH1 gene, which encodes for the protein 
microcephalin, contains a SNP causing a D314H mutation with a MAF of 0.316. The 
SNP in the CA3 gene, for carbonic anhydrase 3, is another natural variant with a MAF of 
0.489. The SNP in the SH2D3C gene, encoding SH2 domain-containing protein 3C, has a 
MAF of 0.447. Two additional SNPs are present in the PRB1 gene, coding for basic 
salivary proline-rich protein 1, leading to P123Q and R129Q mutations, with 
corresponding MAF values of 0.490 and 0.374. A SNP in the HEPN1 gene with a MAF 
of 0.210 leading to a W37R mutation is notable given that this gene encodes for the 
putative cancer susceptibility gene HEPN1 protein. This protein is expressed in the liver 
and is down-regulated in hepatocellular carcinomas.40  
The SNP in the HEPACAM gene causing the M218V mutation has a MAF of 
0.216. This gene encodes for the hepatocyte cell adhesion molecule and is involved in 
regulating cell-matrix interactions and inhibiting cell growth by suppressing cell 
proliferation.41,42 This SNP is particularly interesting given the relevance of the 
extracellular matrix in the development of Dupuytren’s disease. It has been postulated 
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that the mechanism of contracture is the result of two related processes: first, cell-
mediated contraction of the extracellular matrix leads to physical deformation,43 and 
subsequently continuous matrix remodeling results in the permanence of the contracture.7 
Related fibrotic diseases affecting the liver, heart, lung, and kidney have been associated 
with the unbalanced degradation of extracellular matrix, mediated by matrix 
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP).44,45 
Interestingly, in one study of 12 patients with advanced inoperable gastric carcinoma 
treated with the MMP inhibitor Marimastat (British Biotech Ltd., Oxford, United 
Kingdom) daily for more than one month, half of the patients developed Dupuytren’s 
disease or a frozen shoulder.46 The authors of this study subsequently postulated that the 
development of Dupuytren’s disease in this patient cohort was caused by a decrease in 
the MMP to TIMP ratio, leading to increased synthesis and deposition of collagen and 
connective tissue. Another research group subsequently analyzed both MMP and TIMP 
levels in patients with Dupuytren’s disease. They observed that patients with Dupuytren’s 
contracture, when compared to control patients, had significantly higher serum TIMP-1 
levels (437 ng/mL vs. 321 ng/mL, P < 0.05) and significantly lower MMP to TIMP ratios 
(1.1 vs. 1.5, P < 0.05).47 Additionally, TIMP-1 and TIMP-2 were detectable by 
immunohistochemistry in Dupuytren’s tissue but were undetectable in tissue from the 
control group.47 Both TIMP-1 and TIMP-2 were preferentially accumulated in 
proliferative areas of the palmar fascia in the diseased tissues. 
The SNP in the PPP1R32 gene, encoding protein phosphatase 1 regulatory 
subunit 32, is a novel SNP causing a previously uncharacterized T34S mutation. This is a 
425 amino acid protein that interacts with PPP1CA, the protein phosphatase 1 (PP1) 
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catalytic subunit.48 PP1 is a ubiquitous and conserved protein Serine/Threonine 
phosphatase that is thought to catalyze approximately one third of all protein 
dephosphorylations in eukaryotic cells.49-51 However, the specific role of the PPP1R32 
protein in mediating these processes is not well understood. This novel SNP is 
particularly interesting given that it has not been previously characterized, and this 
particular SNP may be of significance from an etiological standpoint or as a marker of 
disease susceptibility. Additional studies are needed to better clarify the associations 
between this SNP and Dupuytren’s disease. 
Perhaps most notably, a SNP in the MUC4 gene leading to amino acid mutation 
T3670P was observed. This amino acid change was observed in the long splice variant of 
the MUC4 gene. This SNP has not previously been characterized and is present in all 
patients in our Dupuytren’s disease cohort and not observed at all in the control group. 
The MUC4 gene encodes for mucin 4 glycoprotein, which is produced primarily in 
epithelial cells and is thought to play a role in tumor progression.52 A transmembrane 
component of MUC4 acts as an activator for the receptor tyrosine kinase avian 
erythroblastosis oncogene homolog 2 (ERBB2, also referred to as HER2), which is 
overexpressed in a number of human cancers, notably breast and ovarian carcinomas.53 
MUC4 itself has been implicated in a number of human cancers, including pancreatic, 
lung, breast, salivary gland, gall bladder, biliary tract, prostate, and ovarian carcinomas, 
and may potentially be a useful clinical marker for these diseases.54 Interestingly, MUC4 
has recently been characterized as a highly sensitive and specific marker for low-grade 
fibromyxoid sarcoma (LGFMS).55 LGFMS is a fibroblastic neoplasm characterized by 
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alternating collagenous and myxoid regions. Clinically, LGFMS is characterized by a 
protracted course with a tendency for local recurrence and late distant metastases.56 
Although the palmar fibromatosis in Dupuytren’s disease is considered benign, 
Dupuytren’s disease shares certain properties with the malignant fibrosarcoma. 
Histologically, the diseased palmar nodules show marked fibroblast proliferation.5 The 
origins of Dupuytren’s disease are also similar to fibrosarcomas in that both arise from 
mesenchymal cells. Both are also characterized by infiltrative growth, proliferation, and a 
tendency to recur despite treatment. One critical difference, however, is that unlike 
sarcomas, Dupuytren’s disease does not metastasize. Of particular interest, one study has 
shown that patients with Dupuytren’s disease have an increased risk of developing 
sarcomas of connective tissue compared to the general population.57 This suggests that 
there could potentially be co-existing risk factors for the development of both 
Dupuytren’s disease and connective tissue sarcomas, or possibly that they share a 
common etiological mechanism. In a follow-up study of patient records of patients with 
both Dupuytren’s disease and sarcoma, the same research group concluded that neither 
smoking nor diabetes, two established risk factors, can account for why patients with 
Dupuytren’s disease have a higher incidence of sarcoma.58 This finding supports the 
notion that these two diseases share a common pathophysiological pathway, although this 
has yet to be verified. These findings lend additional support for the observed genetic 
associations among our patient cohort with SNPs in genes that are known to play a role in 
malignant tumorigenesis.  
Fibrosis is a hallmark of a multitude of clinical disorders, with Dupuytren’s 
disease being one of the more common manifestations. Fibrosis occurs due to 
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uncontrolled fibroblast activity that produces an overabundance of extracellular collagen. 
Dupuytren’s disease is categorized as a superficial fibromatosis, which also includes 
plantar fibromatoses (Ledderhose’s disease) and penile fibromatoses (Peyronie’s 
disease).59 Abnormal focal nuclear accumulations of β-catenin are present in these 
disease processes.60 β-catenin is a dual function protein that regulates cell-cell adhesion 
as well as gene transcription influencing cell proliferation and survival, and is notably 
part of the canonical Wnt signaling pathway (Figure 3).61 Recently, a large genome-wide 
association study was performed, which identified areas of the genome associated with 
Dupuytren’s disease (Figure 4) and implicated 11 common SNPs at nine different loci in 
the nuclear genome.38 Although these 11 SNPs do not correlate with any of the SNPs we 
have identified in our study, notably, the majority of these identified loci harbor genes 
encoding proteins in the Wnt signaling pathway. Wnt signaling is notable for regulating 
the proliferation of fibroblasts in both cancer and fibromatosis.62 As an example, an 
increase in Wnt signaling in the intestine causes prolongation of the proliferation phase of 
crypt cells, which results in polyp formation and subsequently and increased 
predisposition to developing cancer.63 All in all, the observation that there exist strong 
associations with multiple genes in the Wnt signaling pathway suggests both that this 
pathway confers susceptibility to Dupuytren’s disease but also that genetic factors play a 
major role in the development of this disease. In particular, it appears that common 
genetic variants have a critical causative role in Dupuytren’s disease. Our present study 
proposes a set of genetic variants common to our disease cohort that potentially play a 




Figure 3. Signaling pathways of Wnt and β-catenin. (From Dolmans GH, Werker PM, 
Hennies HC, et al. Wnt signaling and Dupuytren's disease. The New England journal of 




Figure 4. Manhattan plot of the genomewide P values plotted against position on each 
chromosome, with the bold horizontal line indicating the significance threshold. (From 
Dolmans GH, Werker PM, Hennies HC, et al. Wnt signaling and Dupuytren's disease. 
The New England journal of medicine. Jul 28 2011;365(4):307-317) 
 
One particularly exciting observation from our study worth further investigation is 
the role of MUC4 in Dupuytren’s disease. A recent study of MUC4 signaling in human 
pancreatic cancer cell lines demonstrated a close association with the Wnt signaling 
pathway.64 Specifically, the knockdown of MUC4 led to downregulation of lysosomal 
degradation of E-cadherin which in turn induced the formation of the E-cadherin/β-
catenin complex, resulting in downregulation of the Wnt signaling pathway.64 The 
presence of mutated MUC4, as observed in our patient cohort, could potentially 
upregulate Wnt signaling and be one of the mechanistic links between the genetic basis of 
the disease and the abnormal Wnt signaling that is likely directly responsible for the 
fibromatosis (Figure 5). The clarification of this mechanistic pathway has potential 
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implications for treatment of Dupuytren’s disease through the identification of additional 




Figure 5. Proposed contributing mechanism in the pathogenesis of Dupuytren’s disease. 
 
 One recent study has identified TNF as a potential therapeutic target in patients 
with Dupuytren’s disease and is a testament to the utility of determining signaling 
pathways in disease processes.65 In this study, diseased tissues from patients with 
Dupuytren’s disease were collected. Fibroblasts were isolated and cultured. High levels 
of proinflammatory cytokines and immune cells were observed, including activated 
macrophages, which secrete TNF. Notably, the exogenous addition of TNF promoted 
differentiation of palmar dermal fibroblasts in to myofibroblasts, which is the cell directly 
responsible for matrix deposition and contraction in Dupuytren’s disease. The authors 
also observed that TNF stimulation of palmar fibroblasts from Dupuytren’s disease 
patients upregulated Wnt signaling, which notably was not observed in nonpalmar 
fibroblasts from Dupuytren’s disease patients or palmar fibroblasts from unaffected 
individuals.65 This specific action of TNF reflects the localization of disease presentation 
in susceptible patients, though it remains unclear what factors account for the 
susceptibility. Notably, the addition of exogenous DKK, an inhibitor of Wnt ligand 
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binding to the Frizzled receptor (Figure 3), did not affect myofibroblast contractility. This 
suggests that the signaling processes governing myofibroblast activity is likely not 
dependent on the binding of Wnt ligand to their receptor but rather more involved with 
the β-catenin component of the canonical signaling pathway. Lastly, with the addition of 
neutralizing antibodies to TNF, the contractile activity of myofibroblasts from the 
diseased tissue was inhibited and the contractile apparatus was observed to disassemble. 
This study lends credence to the theory that the Wnt/β-catenin signaling pathway is a 
primary mediator in the development of fibrosis. However, the upstream and downstream 
signaling processes remain poorly understood and are an exciting area for continued 
research. 
In summary, with our present study, we did not detect any somatic mutations in 
either the mitochondrial or nuclear genomes of patients with Dupuytren’s disease. 
However, we have identified a set of SNPs that are associated with the disease and may 
potentially play a causative role in this disease. Future directions for this work include 
confirming our findings using Sanger sequencing, as well as increasing the number of 
patients in both the disease and control cohorts. One limitation of this study is that 
because of the vast amounts of genetic data that were analyzed, it is possible that some of 
the SNPs identified are not true associations but are coincidental findings. Performing 
mitochondrial and nuclear sequencing on a larger cohort could potentially account for 
this limitation. Additional investigation of the proposed molecular pathways, such as the 
MUC4 and Wnt signaling pathway interactions in patients with Dupuytren’s disease, 
would be of great benefit. Focused genetic studies to follow-up the mitochondrial and 
nuclear mutations identified by our study could also shed additional light on the disease 
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pathogenesis. Given that several molecular mechanisms have been observed to play a 
role in Dupuytren’s disease, one of the biggest challenges for researchers in this field is to 
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Figure 1. The clinical presentation of Dupuytren’s disease. Early stage disease (a) with 
prominent cord and small nodules, followed by more advanced stage (b) with dimpling at 
the base of the digit, and subsequently advanced stage disease (c) with severe deformity.  
 
Figure 2. Distribution of samples from patient cohort; all samples underwent DNA 
extraction and subsequent mitochondrial sequencing and whole-exome sequencing. 
 
Figure 3. Signaling pathways of Wnt and β-catenin. 
 
Figure 4. Manhattan plot of the genomewide P values plotted against position on each 
chromosome, with the bold horizontal line indicating the significance threshold. 
 






Table 1. Common mitochondrial genomic changes observed in all patients in cohort.  
 
Table 2. Nuclear SNPs leading to amino acid changes observed in all diseased tissue that 
are not present in control tissue. 
 
Table 3. List of mutations in MAFB gene among patient cohort. 
 
Table 4. List of mutations in PRKX gene among patient cohort. 
 
Table 5. 16 genes have been consistently reported to be dysregulated by mRNA 
expression microarray studies in patients with Dupuytren’s disease. 
 
